
Vehicle/IgG control
Cetuximab 20mg/kg 2qw ip
LGX818 20mg/kg qd po
LGX818 + Cetuximab
Last treatment
Tumor Volume (mm3)
1200
800
400
0
22
29
36
43
Days Post Implantation

FIG. 1A


Encorafenib + Cetuximab
Change in Tumor Volume vs. Baseline (%)
50
25
0
-25
-50
1
2
3
4
5
6
7
Individual Animal Number

FIG. 1B


Encorafenib + Binimetinib + Cetuximab
Change in Tumor Volume vs. Baseline (%)
50
25
0
-25
-50
1
2
3
4
5
6
7
8
9
Individual Animal Number

FIG. 1C


Vehicle/IgG control
Cetuximab 20mg/kg 2qw ip
LGX818 20mg/kg qd po
LGX818 + Cetuximab
Last treatment
% Body Weight Difference
15
10
5
0
-5
-10
-15
22
25
28
31
34
37
40
43
Days Post Implantation

FIG. 2


Vehicle/IgG control
LGX818 20mg/kg qd po
MEK162 0.5 mg/kg bid po
LGX818+MEK162
Last treatment
Tumor Volume (mm3)
1200
800
400
0
22
29
36
43
Days Post Implantation

FIG. 3


Vehicle/IgG control
LGX818 20mg/kg qd po
MEK162 0.5 mg/kg bid po
LGX818+MEK162
Last treatment
% Body Weight Difference
15
10
5
0
-5
-10
-15
22
25
28
31
34
37
40
43
Days Post Implantation

FIG. 4


Vehicle/IgG control
Cetuximab 20mg/kg 2qw ip
MEK162 3.5 mg/kg qd po
MEK162 + Cetuximab
Last treatment
Tumor Volume (mm3)
1200
800
400
0
22
29
36
43
Days Post Implantation

FIG. 5


Vehicle/IgG control
Cetuximab 20mg/kg 2qw ip
MEK162 3.5 mg/kg qd po
MEK162 + Cetuximab
% Body Weight Difference
15
10
5
0
-5
-10
-15
22
25
28
31
34
37
40
43
Days Post Implantation

FIG. 6


Vehicle
Cetuximab 20mg/kg 2qw ip
LGX818 20mg/kg qd po
MEK162 3.5 mg/kg bid po
LGX818 + MEK162
LGX818 + Cetuximab
MEK162 + Cetuximab
LGX818 + MEK 162 + Cetuximab
Treatment
Tumor Volume (mm3)
2000
1600
1200
800
400
0
22
29
36
43
50
57
64
Days of Post Implantation

FIG. 7


1700
1600
1500
1400
1300
1200
1100
1000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
(In (Counts)
0
10
20
30
2-Theta-Scale

FIG. 8